Nektar Therapeutics

NKTR
Delayed Nasdaq - 04/24 09:59:59 pm
31.15USD
-1.49%
Prev.31.6200
Open31.7000
High31.7000
Low30.2400
Volume1 686 678
Financials
Sales 2019 121 M
EBIT 2019 -501 M
R. net 2019 -503 M
Tréso. 2019 1 671 M
Rend. 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 31,6x
EV / Sales 2020 22,1x
Capitalization 5 505 M
Company
Nektar Therapeutics specializes in the research and development of drugs for the treatment of cancer, autoimmune diseases and chronic pain. Net sales break down by source of income as follows:
- revenues from licensing and collaboration agreements (91.9%);
- product sales (4.6%);
- royalties...
Sector :
Biotechnology & Medical Research - NEC
Calendar :
2019-05-06 Earnings Release
Trading Rating :
Investor Rating :
Latest news
04/24S&P 500 closes at record high, even as EPS growth stagnates
RE
04/02NEKTAR THERAPEUTICS : Presents Preclinical Data on its Immuno-Oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019
PU
04/01NEKTAR THERAPEUTICS : Vaccibody AS and Nektar Therapeutics Present New Preclinical Data from their Immuno-Oncology Collaboration at the American Association for Cancer Research (AACR) Annual Meeting 2019
PU
03/07Merck KGaA, Pfizer added to BioXcels pancreatic cancer deal
AQ
03/06NEKTAR THERAPEUTICS : to Webcast Presentation at the Cowen and Company 39th Annual Health Care Conference
PR
03/01NEKTAR THERAPEUTICS : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
03/01NEKTAR THERAPEUTICS : Presents Preliminary Immune Activation, Safety and Clinical Activity Data from the Ongoing Dose-Escalation Stage of the REVEAL Study at 2019 ASCO-SITC Meeting
PR
03/01NEKTAR THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)
AQ
Technical analysis trends
Short TermMid-TermLong Term
TrendBearishNeutralBearish
Resistance33,646,454,1
Spread/Res.-7,4%-33%-42%
Spread/Supp.0,48%2,4%1,7%
Support31,030,430,6